NEWS

Heading 2

Seal Rock Therapeutics Announces Completion of Single Ascending Dose Cohort in Phase 1 Clinical Trial of ASK1 Inhibitor SRT-015 for NASH

October 18, 2021

Read More  |

Download PDF

Seal Rock Therapeutics Announces Initiation of Phase 1 Clinical Trial of ASK1 Inhibitor SRT-015 for NASH

June 23, 2021

Read More  |

Download PDF

Seal Rock Therapeutics Presents Data Highlighting Superior Efficacy of ASK1 Inhibitor, SRT-015, to Selonsertib for NASH

Nov 16, 2020  |

Read More  |

Download PDF

Seal Rock Therapeutics Announces Upcoming Presentations at AASLD’s The Liver Meeting® 2020

Nov 2, 2020  | 

Read More  |

Download PDF

Seal Rock Therapeutics Advancing Differentiated ASK1 Inhibitor Lead Candidate SRT-015 in NASH

Nov 9, 2018  |

Read More  |

Download PDF